| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Dogwood Therapeutics, Inc.
13D/A
Amendment 4
DWTX · 92829J203
|
75.2% |
10/27/2026
Event 10/26/2026
|
|||
| Sealbond Limited | 67.8% | ||||
| CK Life Sciences Int'l., (Holdings) Inc. | 75.2% | ||||
| Conjoint Inc. | 7.4% | ||||
|
Dogwood Therapeutics, Inc.
13D/A
Amendment 3
DWTX · 92829J203
|
72.3% |
10/21/2026
Event 10/19/2026
|
|||
| Sealbond Limited | 63.9% | ||||
| CK Life Sciences Int'l., (Holdings) Inc. | 72.3% | ||||
| Conjoint Inc. | 8.3% | ||||
|
Dogwood Therapeutics, Inc.
13D/A
Amendment 2
DWTX · 92829J203
|
83.0% |
11/25/2025
Event 11/21/2025
|
|||
| Sealbond Limited | 73.4% | ||||
| CK Life Sciences Int'l., (Holdings) Inc. | 83.0% | ||||
| Conjoint Inc. | 9.6% | ||||
|
Dogwood Therapeutics, Inc.
13D/A
Amendment 1
DWTX · 92829J203
|
15.9% |
3/17/2025
Event 3/12/2025
|
|||
| Sealbond Limited | 15.9% | ||||
| CK Life Sciences Int'l., (Holdings) Inc. | 15.9% | ||||
| Conjoint Inc. | 0% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.